Cryoport, Inc.(CYRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Cryoport, Inc. (CYRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CYRX at 29.0/100 on a 32-signal composite quality model, placing it at rank #2,539 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (14.6) and free cash flow (16.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cryoport, Inc. reports quarterly revenue of $49.0M, net income of $-8.3M, an operating margin of -20.5%. Top institutional holders of CYRX by reported 13-F value include BlackRock, CADIAN CAPITAL MANAGEMENT, MORGAN STANLEY, based on the most recent SEC filings. CYRX trades on the Nasdaq exchange and files with the SEC under CIK 1124524. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cryoport, Inc. directly from SEC EDGAR.